Beauty Health (SKIN) Scheduled to Post Earnings on Thursday

Beauty Health (NASDAQ:SKIN) will be announcing its earnings results after the market closes on Thursday, May 9th. Analysts expect the company to announce earnings of ($0.14) per share for the quarter. Beauty Health has set its Q1 2024 guidance at EPS.Parties that are interested in participating in the company’s conference call can do so using this link.

Beauty Health (NASDAQ:SKIN) last posted its quarterly earnings data on Tuesday, March 12th. The company reported ($0.07) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.04. The business had revenue of $96.80 million during the quarter, compared to the consensus estimate of $87.22 million. Beauty Health had a negative return on equity of 18.85% and a negative net margin of 25.65%. Beauty Health’s quarterly revenue was down 1.3% on a year-over-year basis. During the same period in the prior year, the business posted $0.03 earnings per share. On average, analysts expect Beauty Health to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Beauty Health Price Performance

Beauty Health stock opened at $3.37 on Wednesday. The firm has a market cap of $415.96 million, a P/E ratio of -4.38 and a beta of 1.13. The stock’s 50 day moving average is $3.69 and its 200 day moving average is $3.30. The company has a debt-to-equity ratio of 12.43, a current ratio of 6.07 and a quick ratio of 5.28. Beauty Health has a one year low of $1.35 and a one year high of $11.16.

Analyst Upgrades and Downgrades

SKIN has been the topic of a number of analyst reports. Piper Sandler reaffirmed an “underweight” rating and issued a $3.00 price objective (up from $2.00) on shares of Beauty Health in a research note on Wednesday, March 13th. Stifel Nicolaus reiterated a “hold” rating and set a $4.00 price target (up from $3.00) on shares of Beauty Health in a report on Wednesday, March 13th. TD Cowen lifted their price objective on Beauty Health from $2.50 to $4.00 and gave the stock a “market perform” rating in a research report on Wednesday, March 13th. Canaccord Genuity Group upped their target price on Beauty Health from $3.00 to $4.00 and gave the company a “hold” rating in a research report on Thursday, March 14th. Finally, DA Davidson reiterated a “buy” rating and issued a $5.00 target price on shares of Beauty Health in a report on Friday, March 15th. Three analysts have rated the stock with a sell rating, seven have issued a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat, Beauty Health presently has a consensus rating of “Hold” and an average price target of $6.50.

Beauty Health Company Profile

The Beauty Health Company designs, develops, manufactures, markets, and sells aesthetic technologies and products worldwide. The company's flagship product includes HydraFacial that enhance the skin to cleanse, extract, and hydrate the skin with proprietary solutions and serums. Its products also comprise Syndeo, a Delivery System designs to connects providers to the consumer's preferences to create a more personalized experience; consumables, such as single-use tips, solutions, and serums used to provide a hydrafacial treatment; SkinStylus SteriLock Microsystem, a microneedling device used for the treatment of enhancing appearance of surgical or traumatic hypertrophic scars on the abdomen and facial acne scarring in Fitzpatrick skin types I, II, and III; and Keravive, a treatment for scalp health.